Everolimus + Ranibizumab

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Choroidal Neo-Vascular Age-onset Macular Degeneration

Conditions

Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration

Trial Timeline

Feb 1, 2009 → —

NCT ID

NCT00857259

About Everolimus + Ranibizumab

Everolimus + Ranibizumab is a phase 2 stage product being developed by Novartis for Choroidal Neo-Vascular Age-onset Macular Degeneration. The current trial status is terminated. This product is registered under clinical trial identifier NCT00857259. Target conditions include Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration.

What happened to similar drugs?

7 of 16 similar drugs in Choroidal Neo-Vascular Age-onset Macular Degeneration were approved

Approved (7) Terminated (0) Active (9)

✅Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved

✅ranibizumabNovartisApproved

✅RanibizumabNovartisApproved

🔄Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3

🔄ranibizumabNovartisPhase 3

🔄RanibizumabNovartisPhase 3

🔄ranibizumabNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00857259	Phase 2	Terminated	Feb 1, 2009	—	Choroidal Neo-Vascular Age-onset Macular Degeneration

Competing Products

20 competing products in Choroidal Neo-Vascular Age-onset Macular Degeneration

See all competitors

Product	Company	Stage	Hype Score
Zimura + Eylea	Astellas Pharma	Phase 2	27
Avacincaptad Pegol	Astellas Pharma	Phase 2	35
Verteporfin Photodynamic Therapy + Ranibizumab	Novartis	Approved	43
ranibizumab	Novartis	Approved	43
Ranibizumab	Novartis	Approved	43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT	Novartis	Phase 3	40
ranibizumab	Novartis	Phase 3	40
Ranibizumab	Novartis	Phase 3	40
ranibizumab 0.5mg	Novartis	Phase 2	35
ranibizumab	Novartis	Phase 3	40
Brolucizumab 6mg + Brolucizumab 6mg	Novartis	Phase 3	40
Intravitreal injection ranibizumab	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 3	40
Ranibizumab	Novartis	Phase 1/2	32
Faricimab + Ranibizumab + Sham Procedure	Roche	Phase 2	35
Faricimab + Ranibizumab	Roche	Phase 3	44
Faricimab + Ranibizumab + Sham Procedure	Roche	Phase 2	35
Intravitreal Pegaptanib	Pfizer	Pre-clinical	18
Intravitreal aflibercept injection 2.0mg	Regeneron Pharmaceuticals	Approved	43
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Regeneron Pharmaceuticals	Pre-clinical	26